**Table S3: Clinical characteristics of the DILI groups and healthy subjects in Center 2.**

| Characteristics | **Total DILI(*n*=21)** | **Group Ⅰ****0~6 M DILI(*n*=15)** | **Group Ⅱ****>6 M DILI(*n=*6)** | **Healthy subjects****(n=14)** | **Ⅰ vs Ⅱ*****P* value** |
| --- | --- | --- | --- | --- | --- |
| **Median age / Year (25, P75)** | 60(45, 69) | 54.00(42, 68) | 68(58, 72) | 39 (31, 47) | 0.139 |
| **Female / n(%)** | 13 (66.7) | 10 (66.7) | 3 (50.0) | 5 (35.7)  | 0.488 |
| **ALT / U·L-1(P25, P75)** | 155.00(103.00, 531.00) | 266.00(109.00, 651.00) | 139.00(89.05, 256.00) | 29.38(12.56, 46.20) | 0.243 |
| **AST / U·L-1(P25, P75)** | 135.00(65.00, 239.00) | 135.00(64.00, 248.00) | 121.00(65.00, 256.00) | 24.0 (20.0,29.5) | 0.846 |
| **ALP / U·L-1(P25, P75)** | 111.00(80.50, 170.00) | 101.00(80.00, 182.00) | 134.00(102.00, 165.00) | 64.83(34.75, 94.91) | 0.414 |
| **TBil / µmol·L-1(P25, P75)** | 34.80(17.00, 98.00) | 36.60(12.60, 128.00) | 25.85(27.80, 66.70) | 11.49 (6.32, 16.66) | 0.876 |
| **INR / IU(P25, P75)** | 1.03(0.97, 1.07) | 1.02(0.93, 1.07) | 1.06(1.05, 1.07) | 0.9 (0.7, 1.1) | 0.146 |
| **IgG / g·L-1(P25, P75)** | 12.98(10.54, 13.99) | 11.25(8.07, 15.38) | 13.90(13.21, 14.02) | 12.31 (8.23, 15.6) | 0.088 |
| **IgM / g·L-1(P25, P75)** | 1.06(0.67, 1.48) | 1.33(0.86, 1.48) | 0.72(0.48, 1.44) | 1.43 (0.6, 2.1) | 0.461 |
| **Positive rate of autoantibody\* / %** | 23.8 | 20.0 | 33.3 | 0 | 0.316 |

\* Positive rate of autoantibodies included antinuclear antibodies, smooth muscle antibodies, antimitochondrial antibodies and anti-parietal cell antibodies; *P* value: 0~6 M DILI *vs* >6 M DILI.